NCT00295165终止3 期
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease
Genzyme, a Sanofi Company0 个研究点目标入组 33 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 33
- 主要终点
- To induce clinical remission and/or clinical response following 8 weeks of treatment
研究概览
简要总结
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
详细描述
On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Male or female, age >/= 18 years
- •Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at least 4 months prior to receiving the first dose of study drug
- •Moderately to severely active Crohn's disease at time of screening (i.e., CDAI greater than or equal to 220 and less than or equal to 475 points)
- •If under treatment for Crohn's disease, medication must be stable for at least 4 weeks prior to receiving the first dose of study drug. The following therapies are allowed:
- •Oral therapy with salicylates (mesalamine, sulfasalazine, olsalazine, or balsalazide) for Crohn's disease
- •Antibiotics or probiotics for Crohn's disease
- •Topical rectal therapy with mesalamine
- •Females of child-bearing potential:
- •Negative pregnancy test within 72 hours prior to receiving the first dose of study drug
- •Sexually-active males and females of child-bearing potential:
- •Agreement to use adequate method of contraception throughout the study
- •Ability to self-inject study drug or availability of a designee who can do so
排除标准
- •Pregnancy or breast-feeding
- •Colostomy or ileostomy
- •Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage
- •GI surgery within 6 months prior to receiving the first dose of study drug
- •Symptoms of bowel obstruction or confirmed evidence of a clinically-significant stricture within the last 6 months that has not been surgically corrected
- •Positive stool test results for any of the following:
- •Salmonella spec.
- •Shigella spec.
- •Campylobacter spec.
- •Bacterial toxin:
- •Clostridium difficile
- •Ova and parasites:
- •Amoeba spec.
- •Giardia spec.
- •Cryptosporidium spec.
- •Any of the following laboratory abnormalities:
- •Serum creatinine >/= 2.0 mg/dL
- •Alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin >/=; 2 x the upper limit of normal
- •Hemoglobin (Hgb) < 8.0 g/dL
- •Absolute neutrophil count (ANC) </= 1,000 cells/µL or > cells 20,000/µL
- •Planned in-patient hospitalization during the study
- •Presence or history of cancer of any type (except treated basal cell carcinoma) or definite dysplasia of the colon within the last 5 years
- •Use of any of the following medications during the specified period of time prior to receiving the first dose of study drug:
- •At any time:
- •Recombinant human GM CSF (sargramostim or molgramostim)
- •Granulocyte colony-stimulating factor (G CSF; filgrastim or pegfilgrastim)
- •Natalizumab 8 weeks: or 5 half-lives (whichever is longer)
- •Licensed/registered and/or experimental anti-tumor necrosis factor (TNF) therapy such as infliximab or adalimumab 4 weeks:
- •6-mercaptopurine
- •Azathioprine
- •Cyclophosphamide
- •Methotrexate
- •Mycophenolate mofetil
- •Tacrolimus
- •Cyclosporine
- •Thalidomide
- •Glucocorticoids, including budesonide and prednisone, or local glucocorticoid therapy for Crohn's disease
- •Any other immunosuppressive drugs
- •Use of any investigational drug within 4 weeks or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug
- •Use of nutritional therapy (parenteral nutrition or enteral nutrition with elemental or semi-elemental diets) within 4 weeks prior to receiving the first dose of study drug. If the physician judges that nutritional supplementation is needed, enteral nutritional supplements will be allowed for patients who have been receiving a stable regimen for at least 4 weeks prior to receiving the first dose of study drug and that is intended to continue through the 8 week treatment period.
- •History of allergy to yeast products or to sargramostim or to any other excipient of the study drug formulation
- •Active drug or alcohol abuse
- •Clinically important co-morbid conditions unrelated to Crohn's disease as determined by the investigator
- •Previous randomization into this study, or into any other study of the sponsor's sargramostim development program
研究组 & 干预措施
Arm 2
Placebo Comparator
干预措施: Placebo (Drug)
Arm 1
Experimental
干预措施: Sargramostim (Leukine) (Drug)
结局指标
主要结局
To induce clinical remission and/or clinical response following 8 weeks of treatment
时间窗: 8 weeks
次要结局
- To assess the safety profile of sargramostim (including development of antibodies against sargramostim)(During study treatment)
- To assess quality of life (QoL)(During study treatment)
研究者
相似试验
已完成
3 期
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's DiseaseCrohn DiseaseNCT00206674Genzyme, a Sanofi Company286
已完成
2 期
Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's DiseaseCrohn DiseaseNCT00206596Genzyme, a Sanofi Company127
进行中（未招募）
4 期
Benefits of lutein in management of eye stress due to long hours of computer usageCTRI/2022/12/048392Olive life sciences (Pvt) ltd
终止
3 期
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With SargramostimCrohn DiseaseNCT00206713Genzyme, a Sanofi Company264
已完成
1 期
Single Ascending Dose Study of Lu AF76432 in Healthy Young MenHealthyNCT03531229H. Lundbeck A/S42